Allogene Therapeutics, Inc. Common Stock
Here’s whether Allogene Therapeutics, Inc. Common Stock (ALLO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +15.2%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.82% over 10 days); RSI 27 — oversold; 3-month momentum negative (-24.7%). Currently 61.0% off its 52-week high. Score: -5/7.
ALLO is trading below its 200-day MA ($1.85) — a key warning sign the longer-term trend is under pressure. An RSI of 26.7 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +15.2% compares to +16.5% for SPY (trailed the market by 1.2%). The current 61.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.